CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with Atezolizumab to Treat Gastric Cancer February 8, 2023
ASCO GI: 84% Overall Survival at 18 Months from Ph 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma announced February 1, 2023
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab January 4, 2023
Enhertu approved in the EU for patients with previously treated HER2-positive advanced gastric cancer January 4, 2023
Zolbetuximab Meets Primary Endpoint in Ph 3 GLOW Trial as 1L Treatment in Claudin 18.2 +ve HER2-neg Locally Advanced Unresectable or Metastatic GEJ Cancers December 19, 2022
Ph 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma November 30, 2022
Positive Topline Result in Fruquintinib Ph 3 FRUTIGA Study in 2L Gastric Cancer in China announced November 23, 2022
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer November 23, 2022
First Patient Enrolled in Part C of Ph 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer October 19, 2022
